- Home
- ARMP vs DTIL Comparison
ARMP vs DTIL Comparison
Compare ARMP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- DTIL
- Stock Information
- Founded
- ARMP N/A
- DTIL 2006
- Country
- ARMP United States
- DTIL United States
- Employees
- ARMP N/A
- DTIL N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- DTIL Health Care
- Exchange
- ARMP Nasdaq
- DTIL Nasdaq
- Market Cap
- ARMP 52.1M
- DTIL 51.6M
- IPO Year
- ARMP N/A
- DTIL 2019
- Fundamental
- Price
- ARMP $2.22
- DTIL $4.49
- Analyst Decision
- ARMP Strong Buy
- DTIL Strong Buy
- Analyst Count
- ARMP 1
- DTIL 2
- Target Price
- ARMP $9.00
- DTIL $47.00
- AVG Volume (30 Days)
- ARMP 18.4K
- DTIL 549.2K
- Earning Date
- ARMP 08-12-2025
- DTIL 07-31-2025
- Dividend Yield
- ARMP N/A
- DTIL N/A
- EPS Growth
- ARMP N/A
- DTIL N/A
- EPS
- ARMP N/A
- DTIL N/A
- Revenue
- ARMP $4,699,000.00
- DTIL $51,141,000.00
- Revenue This Year
- ARMP $8.43
- DTIL N/A
- Revenue Next Year
- ARMP N/A
- DTIL $53.21
- P/E Ratio
- ARMP N/A
- DTIL N/A
- Revenue Growth
- ARMP 14.24
- DTIL N/A
- 52 Week Low
- ARMP $0.90
- DTIL $3.61
- 52 Week High
- ARMP $3.42
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- ARMP 63.56
- DTIL 54.93
- Support Level
- ARMP $1.93
- DTIL $4.08
- Resistance Level
- ARMP $2.24
- DTIL $4.38
- Average True Range (ATR)
- ARMP 0.16
- DTIL 0.28
- MACD
- ARMP 0.03
- DTIL 0.05
- Stochastic Oscillator
- ARMP 104.55
- DTIL 85.26
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.